



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 47506 (47843)

Patent application of

#10

MARCHIONNI, MARK et al.

Serial No. 09/756,481

Filed: January 8, 2001

For: METHODS FOR TREATING NEUROLOGICAL INJURIES AND DISORDERS

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and

3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United


Serial No. 09/756,481

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,


August 8, 2002

Date


James A. Coburn

HARBOR CONSULTING
Intellectual Property Services
1500A Lafayette Road
Suite 262
Portsmouth, N.H.
800-318-3021

03C0

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant application of: M. Marchionni et al.
 Application No.: 09/756,481 GROUP: 1614
 Filed: January 18, 2001 EXAMINER: Not Yet Assigned
 For: METHODS FOR TREATING NEUROLOGICAL INJURIES AND DISORDERS

Assistant Commissioner for Patents
 Washington, D.C. 20231
 BOX: PCT

**SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,
 AND/OR AMENDMENT PERTAINING THERETO
 FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE
 AND/OR AMINO ACID SEQUENCE**

(check and complete this item, if applicable)

1. [X] This replies to the Office Letter DATED July 3, 2002.

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the application number from the return post card or the attorney's docket number added.

- [X] A copy of the Office Letter is enclosed.

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, Christine C. O'Day
(type or print name of person signing below)

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- [X] deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: 8/27/02

FACSIMILE

- [] transmitted by facsimile to the Patent and Trademark Office.

Susan M Dillon
 Signature

Susan M. Dillon
(type or print name of person certifying)

state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith is/are:

(check each item as applicable)

- A. "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. Section 1.821(c) and 37 C.F.R. Sections 1.822 and 1.823.
- B. An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. Section 1.821(d).
- C. A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. Sections 1.821(e) and 1.824.
- D. Please transfer to this application, in accordance with 37 C.F.R. Section 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of:

Application No.: 0 /

Filed:

For:

Group No.:

Examiner:

The Computer readable form(s) of applicant's other application corresponds to the "Sequence Identifier(s)" of the application as follows:

Computer Readable Form

"Sequence Identifier"

(other application)

(this application)

NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference maybe made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. Section 1.821(e).

- E. A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. Section 1.821(g).

Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. Section 1.821(b).

F. Because this submission is made in fulfilling the requirement under 37 C.F.R. Section 1.821(g), a statement that the submission includes no new matter.

Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. Section 1.821(g).

**STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER**

4. I hereby state:

(complete applicable item A and/or B)

A. Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.

B. All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

STATUS

5. Applicant is

a small entity.

other than a small entity.

EXTENSION OF TERM

6.

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).

NOTE: See 37 C.F.R. Section 1.645 for extensions of time in interference proceedings and 37 C.F.R. Section 1.550(c) for extensions of time in reexamination proceedings.

7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. Section 1.136 apply.

(complete (a) or (b) as applicable)

(a) Applicant petitions for an extension of time under 37 C.F.R. Section 1.136 (fees: 37 C.F.R. Section 1.17(a)(1)-(4)) for the total number of months checked below:

Extension (months)	Fee for other than <u>small entity</u>	Fee for <u>small entity</u>
[] one month	\$ 110.00	\$ 55.00
[] two months	\$ 400.00	\$ 200.00
[] three months	\$ 920.00	\$ 460.00
[] four months	\$1,440.00	\$ 720.00

Fee \$ _____

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

[] An extension for _____ months has already been secured, and the fee paid therefor of \$ _____ is deducted from the total fee due for the total months of extension now requested.

Extension fee due with this request \$_____

OR

(b) [X] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.

FEE PAYMENT

8. [] Attached is a check in the sum of \$ _____.

[] Charge Account No. _____ the sum of \$ _____.
A duplicate of this transmittal is attached.

FEE DEFICIENCY

9.

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.

10. [X] If any additional extension and/or fee is required, charge Account No. 04-1105.

SIGNATURE(s)

Christine C. O'Day
(type or print name of person signing statement)

Christine C. O'Day

Signature

8-27-02

Date

EDWARDS & ANGELL, LLP

P.O. Box 9169

P.O. Address of Signatory

Boston, MA 02209

(If applicable)

Tel. No.: (617) 439-4444

Reg. No. 38,256

Customer No.: 21874

- Inventor
- Assignee of complete interest
- Person authorized to sign on behalf of assignee
- Practitioner of record
- Filed under Rule 34(a)
- Registration No.
- Other

(complete the following, if applicable)

(type name of assignee)

Address of assignee

Title of person authorized to sign on behalf of assignee


A "STATEMENT UNDER 37 C.F.R. Section 3.73(b)" is attached.

Assignment recorded in PTO on _____

Reel _____ Frame _____



DCC/PJC
47506
7/10/02



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/756,481	01/08/2001	Mark Marchionni	47506 (71095)

Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
Edwards & Angell, LLP
P.O. Box 9169
Boston, MA 02209

RECEIVED	CONFIRMATION NO. 4213
JUL 08 2002	
KRD	
EDWARDS & ANGELL, LLP DIKE BRONSTEIN ROBERTS CUSHMAN	
OC000000008358557*	

Date Mailed: 07/03/2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

[Signature]
 Customer Service Center
 Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

Sequence listing
 Edwards & Angell LLP
 Dike, Bronstein, Roberts & Cushman
 101 Federal St. Boston, MA 02110
 Date Rec'd 7/10/02
 Docketed For Sys 3, 2002 - 7/11, 3, 2002
 By KRD
 Approved M - 7/11/02



Raw Sequence Listing Error Summary

<u>ERROR DETECTED</u>	<u>SUGGESTED CORRECTION</u>	<u>SERIAL NUMBER:</u> <u>09 756 487 A</u>
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOI		
1 <input type="checkbox"/> Wrapped Nucleic Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."	
2 <input type="checkbox"/> Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.	
3 <input type="checkbox"/> Misaligned Amino Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.	
4 <input type="checkbox"/> Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.	
5 <input type="checkbox"/> Variable Length	Sequence(s) _____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.	
6 <input type="checkbox"/> PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	
7 <input type="checkbox"/> Skipped Sequences (OLD RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (ii) SEQUENCE DESCRIPTION: SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped	
8 <input type="checkbox"/> Skipped Sequences (NEW RULES)	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.	
9 <input type="checkbox"/> Use of n's or Xaa's (NEW RULES)	Sequence(s) _____ missing. If Intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000	
10 <input type="checkbox"/> Invalid <213> Response	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
11 <input checked="" type="checkbox"/> Use of <220>	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence	
12 <input type="checkbox"/> PatentIn 2.0 "bug"	Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)	
13 <input type="checkbox"/> Misuse of n	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.	

AMC/MH - Biotechnology Systems Branch - 08/21/2001

The type of errors shown exist throughout the Sequence Listing. Please check subsequent sequences for similar errors.



OIPE

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/756,481A

DATE: 10/02/2001
TIME: 11:48:10

Input Set : A:\47506-sequence.txt
Output Set: N:\CRF3\10022001\I756481A.raw

3 <110> APPLICANT: Mark Marchionni
 4 Michael Jarpe
 5 Ted Ebendal
 7 <120> TITLE OF INVENTION: METHODS FOR TREATING NEUROLOGICAL
 8 INJURIES AND DISORDERS
 10 <130> FILE REFERENCE: 47506 (71095)
 12 <140> CURRENT APPLICATION NUMBER: 09/756,481A
C--> 13 <141> CURRENT FILING DATE: 2001-08-30
 15 <150> PRIOR APPLICATION NUMBER: PCT/US99/15106
 16 <151> PRIOR FILING DATE: 1999-07-02
 18 <150> PRIOR APPLICATION NUMBER: 60/091,791
 19 <151> PRIOR FILING DATE: 1998-07-06
 21 <160> NUMBER OF SEQ ID NOS: 2
 23 <170> SOFTWARE: FastSEQ for Windows Version 3.0
 25 <210> SEQ ID NO: 1
 26 <211> LENGTH: 1387
 27 <212> TYPE: DNA
 28 <213> ORGANISM: Artificial Sequence
 30 <220> FEATURE:
 31 <221> NAME/KEY: CDS
 32 <222> LOCATION: (218)...(1288)

Does Not Comply
Corrected Diskette Needed

A 213 response of "Artificial Sequence" requires an explanation or description in field 223

W--> 34 <223> OTHER INFORMATION: Erroneous

34 <400> SEQUENCE:	1					
35 cccttctcca	gggactctgg	ctgccagcag	ctccgccttt	cagatcaatt	ctcgaccacc	60
36 caccttggaa	ctgcccggca	gtcctgcctt	ctggatcagt	gggggtccaga	cacccccct	120
37 ccaggacctc	aaagcacccc	cgacctaagg	tcaccagccc	actggccca	gacgcagtgg	180
38 gctccgctga	ctctcttgaa	cacccctgg	gaggaaa	atg ctc cct	gtc tgc cat	235
39				Met	Leu Pro Val Cys His	
40				1	5	
42 cgt ttt tgc	gac cac ctc	ctc ctc ctg	ctc ttg	ctg ccc	tcg acg acc	283
43 Arg Phe Cys Asp	His Leu Leu Leu	Leu Leu Leu Leu	Leu Leu Leu	Pro Ser Thr	Thr	
44	10	15	20			
46 ctg gcc ccc	gcg cca gca	tcc atg ggc	ccc gct	gcc ctc	cag 331	
47 Leu Ala Pro	Ala Pro Ala	Ser Met Gly	Pro Ala Ala	Ala Leu Leu	Gln	
48	25	30	35			
50 gtt ctt ggg	ctt ccc gaa	gca gcg	ccc cgg	agc gtc	ccc aca cac cga cct	379
51 Val Leu Gly	Leu Pro Glu	Ala Pro Arg	Ser Val	Pro Thr His	Arg Pro	
52	40	45	50			
53 gtg cct gtc	atg tgg cgc	cta ttc cgt	cgc cgt	gac ccc	cag gag 427	
54 Val Pro Pro	Val Met Trp	Arg Leu Phe	Arg Arg	Asp Pro Gln	Glu	
55	55	60	65	70		
57 gcc aga gtg	gga cgc cct	ctg cgg cca	tgc cac	gtg gag	gaa cta ggg 475	
58 Ala Arg Val	Gly Arg Pro	Leu Arg Pro	Cys His	Val Glu Glu	Leu Gly	
59	75	80	85			
61 gtc gcc gga	aac att gtg	cgc cac atc	ccc gac	agc ggt	ctg tcc tcc 523	
62 Val Ala Gly	Asn Ile Val	Arg His Ile	Pro Asp	Ser Gly	Leu Ser Ser	
63	90	95	100			

The type of errors shown exist throughout the Sequence Listing. Please check subsequent sequences for similar errors.

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/756,481A

DATE: 10/02/2001
TIME: 11:48:10

Input Set : A:\47506-sequence.txt
Output Set: N:\CRF3\10022001\I756481A.raw

65	agg ccc gca caa ccc gcc agg acc tcg ggg ctg tgc ccc gag tgg aca	571
66	Arg Pro Ala Gln Pro Ala Arg Thr Ser Gly Leu Cys Pro Glu Trp Thr	
67	105 110 115	
69	gtc gtc ttt gac ctg tcg aat gtg gag ccc aca gag cgc cca aca cgc	619
70	Val Val Phe Asp Leu Ser Asn Val Glu Pro Thr Glu Arg Pro Thr Arg	
71	120 125 130	
73	gct cgc tta gag ttg cgg ctg gag gct gag tgt gaa gat aca gga ggg	667
74	Ala Arg Leu Glu Leu Arg Leu Glu Ala Glu Cys Glu Asp Thr Gly Gly	
75	135 140 145 150	
77	tgg gag cta agc gtg gca ctg tgg gcc gac gca gag cat cca ggg cct	715
78	Trp Glu Leu Ser Val Ala Leu Trp Ala Asp Ala Glu His Pro Gly Pro	
79	155 160 165	
81	gag ctg ctg cgc gtg ccg cgc cca cca ggg gtg ctc ctg cgc gca gac	763
82	Glu Leu Leu Arg Val Pro Ala Pro Pro Gly Val Leu Leu Arg Ala Asp	
83	170 175 180	
85	cta ctg ggg act gca gta gcc gcc aac gca tca gtg ccc tgt act gtg	811
86	Leu Leu Gly Thr Ala Val Ala Ala Asn Ala Ser Val Pro Cys Thr Val	
87	185 190 195	
89	cgc ctg gcg ctg tca ctg cac cct ggg gcc act gca gcc tgt ggg cgc	859
90	Arg Leu Ala Leu Ser Leu His Pro Gly Ala Thr Ala Ala Cys Gly Arg	
91	200 205 210	
93	ctg gct gag gcc tcc ctg ctg gtg acg ctg gac cca cgc ctg tgt	907
94	Leu Ala Glu Ala Ser Leu Leu Leu Val Thr Leu Asp Pro Arg Leu Cys	
95	215 220 225 230	
97	ccc ttg ccg cga ttg cgg cgc cac acg gag ccc agg gta gaa gtt ggt	955
98	Pro Leu Pro Arg Leu Arg Arg His Thr Glu Pro Arg Val Glu Val Gly	
99	235 240 245	
101	cca gtg ggc act tgt cgt acc cga cgg ttg cat gtg agc ttc cgt gag	1003
102	Pro Val Gly Thr Cys Arg Thr Arg Arg Leu His Val Ser Phe Arg Glu	
103	250 255 260	
105	gtg ggc tgg cac cgt tgg gtg atc gcg ccg cgt ggc ttc cta gcc aac	1051
106	Val Gly Trp His Arg Trp Val Ile Ala Pro Arg Gly Phe Leu Ala Asn	
107	265 270 275	
109	tcc tgc cag ggc acg tgc gca cta ccc gaa acg ctg agg gga ccc ggc	1099
110	Phe Cys Gln Gly Thr Cys Ala Leu Pro Glu Thr Leu Arg Gly Pro Gly	
111	280 285 290	
113	ggg ccg cct gca ctc aac cac gct gtg ctg cgc gcg ctc atg cac gca	1147
114	Gly Pro Pro Ala Leu Asn His Ala Val Leu Arg Ala Leu Met His Ala	
115	295 300 305 310	
117	gct gct ccc acc ccg ggt gca ggc tcg ccc tgc tgc gtg cca gag cgt	1195
118	Ala Ala Pro Thr Pro Gly Ala Gly Ser Pro Cys Cys Val Pro Glu Arg	
119	315 320 325	
121	cta tca ccc atc tcc gtg ctc ttc gac aat agt gac aac gtg gtc	1243
122	Leu Ser Pro Ile Ser Val Leu Phe Asp Asn Ser Asp Asn Val Val	
123	330 335 340	
125	ctg cga cac tac gaa gac atg gtg gtg gat gag tgt ggc tgc cgt	1288
126	Leu Arg His Tyr Glu Asp Met Val Val Asp Glu Cys Gly Cys Arg	
127	345 350 355	
129	tgaccacccg ggacaccctt tcagggaccc cccacgcaa aaggcaggac tgtttgtca	1348

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/756,481A

DATE: 10/02/2001
TIME: 11:48:10

Input Set : A:\47506-sequence.txt
Output Set: N:\CRF3\10022001\I756481A.raw

130 tgttttattt gtgacaaaaa gcttaaaaca aatttgact 1387
 132 <210> SEQ ID NO: 2
 133 <211> LENGTH: 357
 134 <212> TYPE: PRT
 135 <213> ORGANISM: Artificial Sequence
 W--> 137 <220> FEATURE:
 W--> 137 <223> OTHER INFORMATION:
 137 <400> SEQUENCE: 2
 138 Met Leu Pro Val Cys His Arg Phe Cys Asp His Leu Leu Leu Leu
 139 1 5 10 15
 140 Leu Leu Pro Ser Thr Thr Leu Ala Pro Ala Pro Ala Ser Met Gly Pro
 141 20 25 30
 142 Ala Ala Ala Leu Leu Gln Val Leu Gly Leu Pro Glu Ala Pro Arg Ser
 143 35 40 45
 144 Val Pro Thr His Arg Pro Val Pro Pro Val Met Trp Arg Leu Phe Arg
 145 50 55 60
 146 Arg Arg Asp Pro Gln Glu Ala Arg Val Gly Arg Pro Leu Arg Pro Cys
 147 65 70 75 80
 148 His Val Glu Glu Leu Gly Val Ala Gly Asn Ile Val Arg His Ile Pro
 149 85 90 95
 150 Asp Ser Gly Leu Ser Ser Arg Pro Ala Gln Pro Ala Arg Thr Ser Gly
 151 100 105 110
 152 Leu Cys Pro Glu Trp Thr Val Val Phe Asp Leu Ser Asn Val Glu Pro
 153 115 120 125
 154 Thr Glu Arg Pro Thr Arg Ala Arg Leu Glu Leu Arg Leu Glu Ala Glu
 155 130 135 140
 157 Cys Glu Asp Thr Gly Gly Trp Glu Leu Ser Val Ala Leu Trp Ala Asp
 158 145 150 155 160
 159 Ala Glu His Pro Gly Pro Glu Leu Leu Arg Val Pro Ala Pro Pro Gly
 160 165 170 175
 161 Val Leu Leu Arg Ala Asp Leu Leu Gly Thr Ala Val Ala Ala Asn Ala
 162 180 185 190
 163 Ser Val Pro Cys Thr Val Arg Leu Ala Leu Ser Leu His Pro Gly Ala
 164 195 200 205
 165 Thr Ala Ala Cys Gly Arg Leu Ala Glu Ala Ser Leu Leu Leu Val Thr
 166 210 215 220
 167 Leu Asp Pro Arg Leu Cys Pro Leu Pro Arg Leu Arg Arg His Thr Glu
 168 225 230 235 240
 169 Pro Arg Val Glu Val Gly Pro Val Gly Thr Cys Arg Thr Arg Arg Leu
 170 245 250 255
 171 His Val Ser Phe Arg Glu Val Gly Trp His Arg Trp Val Ile Ala Pro
 172 260 265 270
 173 Arg Gly Phe Leu Ala Asn Phe Cys Gln Gly Thr Cys Ala Leu Pro Glu
 174 275 280 285
 175 Thr Leu Arg Gly Pro Gly Gly Pro Pro Ala Leu Asn His Ala Val Leu
 176 290 295 300
 177 Arg Ala Leu Met His Ala Ala Pro Thr Pro Gly Ala Gly Ser Pro
 178 305 310 315 320
 179 Cys Cys Val Pro Glu Arg Leu Ser Pro Ile Ser Val Leu Phe Asp

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/756,481A

DATE: 10/02/2001
TIME: 11:48:10

Input Set : A:\47506-sequence.txt
Output Set: N:\CRF3\10022001\I756481A.raw

180 325 330 335
181 Asn Ser Asp Asn Val Val Leu Arg His Tyr Glu Asp Met Val Val Asp
182 340 345 350
183 Glu Cys Gly Cys Arg
184 355

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/756,481A

DATE: 10/02/2001
TIME: 11:48:11

Input Set : A:\47506-sequence.txt
Output Set: N:\CRF3\10022001\I756481A.raw

L:13 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:34 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:
L:137 M:258 W: Mandatory Feature missing, <220> FEATURE:
L:137 M:258 W: Mandatory Feature missing, <223> OTHER INFORMATION:

STATISTICS SUMMARY
PATENT APPLICATION: US/09/756,481A

DATE: 10/02/2001
TIME: 11:48:11

Input Set : A:\47506-sequence.txt
Output Set: N:\CRF3\10022001\I756481A.raw

Application Serial Number: US/09/756,481A

Alpha or Numeric: Numeric

Application Class:

Application File Date: 08-30-2001

Art Unit: OIPE

Software Application: FastSeq

Total Number of Sequences: 2

Total Nucleotides: 1387

Total Amino Acids: 357

Number of Errors: 0

Number of Warnings: 3

Number of Corrections: 1

MESSAGE SUMMARY

258 W: 3 (Mandatory Feature missing)

271 C: 1 (Current Filing Date differs)